Shattuck Labs, Inc. (NASDAQ:STTK) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $7.50.

A number of equities analysts have recently weighed in on the company. Leerink Partnrs raised Shattuck Labs to a “strong-buy” rating in a research note on Monday, March 17th. Leerink Partners initiated coverage on Shattuck Labs in a research report on Monday, March 17th. They issued an “outperform” rating and a $4.00 target price on the stock.

Shattuck Labs Stock Performance

NASDAQ:STTK opened at $1.20 on Monday. The firm has a market capitalization of $57.29 million, a PE ratio of -0.78 and a beta of 1.66. The stock has a 50-day simple moving average of $1.24 and a two-hundred day simple moving average of $1.58. Shattuck Labs has a 52-week low of $0.94 and a 52-week high of $11.76.

Institutional Investors Weigh In On Shattuck Labs

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STTK. Zacks Investment Management bought a new position in shares of Shattuck Labs during the fourth quarter valued at approximately $25,000. Virtu Financial LLC bought a new position in Shattuck Labs in the fourth quarter worth approximately $30,000. Atom Investors LP bought a new position in Shattuck Labs in the third quarter worth approximately $35,000. Readystate Asset Management LP bought a new position in Shattuck Labs in the third quarter worth approximately $39,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in Shattuck Labs during the 4th quarter valued at $45,000. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.